Clinical biomarkers of angiogenesis inhibition. - Wikidata - awgldk - TriplyDB

Clinical biomarkers of angiogenesis inhibition.

Clinical biomarkers of angiogenesis inhibition.

http://www.wikidata.org/entity/Q37139413

about

Photoacoustic imaging: a potential tool to detect early indicators of metastasis.Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis.Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics Angiogenesis inhibitors: current strategies and future prospects.Confocal laser endomicroscopy for the morphometric evaluation of microvessels in human colorectal cancer using targeted anti-CD31 antibodies Targeting angiogenesis using a C-type atrial natriuretic factor-conjugated nanoprobe and PET.Extracellular NM23 Signaling in Breast Cancer: Incommodus Verum.Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma.A phase 2 study of pegylated interferon α-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma.Computer-aided Image Processing of Angiogenic Histological.Molecular targets for tumor radiosensitization.Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo Molecular MR imaging of neovascular progression in the Vx2 tumor with αvβ3-targeted paramagnetic nanoparticles Role of endothelial cell-selective adhesion molecule in hematogeneous metastasis.Biomarkers and imaging: physics and chemistry for noninvasive analyses.Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.Added value of molecular targeted agents in oncology.Angiogenesis in neuroendocrine tumors: therapeutic applications.Angiogenesis in salivary gland tumors: from clinical significance to treatment.Circulating endothelial cells and their progenitors in acute myeloid leukemia.Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab.Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors.

P2860

Q30447713-49007A03-F00A-44BA-B4BA-F081A6666F26 Q33770947-3AD6B7C1-0D75-4754-BA09-E74A30431627 Q33803564-1C5AC218-BB9A-435F-855A-F19EA3F142EE Q34056376-2055C6AE-3883-4101-A5BC-1F0A61B1432B Q34534648-0A331452-AFC4-4AB3-AE75-7942D5CE1EDF Q34632453-E3671B7E-AF9D-4103-BCA2-A67112B9E563 Q35546643-E853CA98-8F0D-4C19-B1E0-3D1E8ECB9726 Q35739362-2EC30D93-7818-4EBA-B3BE-345FDE76B83D Q35791274-66582C13-9071-421A-A717-7D0F110A4635 Q35849994-FDFEB11F-79C8-47F9-BA16-25F0E9B4A725 Q36126009-C4E573FA-9B1B-4ADC-B753-B657E0D5CEFB Q36710062-E1C23DB4-0EEB-428A-A0AF-76F1BA96B95B Q37039546-3F632E3D-AE17-407E-A43D-0DD55955EEBA Q37651091-C2AFBE1E-B590-40E4-9970-43339DA56743 Q37810197-467CD6D2-244E-46F2-935D-6D82DADBE0AD Q37830361-67CABEF7-54FF-47AA-9100-528EC51A5D84 Q37837267-E758B54A-1617-45C7-A082-AF136DD76EB4 Q38005887-B33F963B-8F6A-4ED2-A62A-C956405124B2 Q38468107-0C0619E0-DDAB-4872-ADB7-A9CC11D2723B Q41153604-728C27E5-846D-4743-ADBE-1D06723F5606 Q42010041-B65FA44B-78C7-49DD-AE1D-1C8798C05242 Q54480921-4341BDDD-4070-45B0-9677-3F3DA1B60967 Q54485562-87B7C317-F51A-4821-A195-8D5673FD1FD8

P2860

Clinical biomarkers of angiogenesis inhibition.

http://www.wikidata.org/entity/Q37139413

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical biomarkers of angiogenesis inhibition.

@en

Clinical biomarkers of angiogenesis inhibition.

@nl

type

label

Clinical biomarkers of angiogenesis inhibition.

@en

Clinical biomarkers of angiogenesis inhibition.

@nl

prefLabel

Clinical biomarkers of angiogenesis inhibition.

@en

Clinical biomarkers of angiogenesis inhibition.

@nl

P1433

Q37139413-21AD4FBF-5A82-411D-8687-828E6C0DCE8C

P1476

Q37139413-2C9DA557-E14F-4480-BC9F-B69ACF07DEA7

P2093

Q37139413-2CADB9F8-F808-4E75-8F9B-C2F50A2A8A3A

Q37139413-3D8D0313-8193-4699-B5E4-A60A59053E12

Q37139413-D92A4769-2020-4423-9146-72099BC7A47B

P2860

Q37139413-00F1F141-73D7-49EC-BA85-E3A7506EBB2A

Q37139413-02636090-05DF-4B3E-8617-9E176B886571

Q37139413-03D5A281-E185-4CCE-8A53-48DB67188DE6

Q37139413-051E4987-6793-4F58-B239-0089D104D5F4

Q37139413-05978295-4398-4D6B-8052-8935366C8463

Q37139413-0A63D75D-09C4-4618-BD12-24949823C05B

Q37139413-0B3008C6-59C7-47C0-801F-0A0A0C6EA83A

Q37139413-0BF66030-B81C-4BDA-8946-F6743164F5C0

Q37139413-0C0B6490-589F-4E51-9F8B-DA563A6F5C5A

Q37139413-0CE9DB39-0D4F-4B8C-8E62-738820B4CFEE

P2888

Q37139413-11679321-7412-4FFA-9877-88B6ED5EA4F7

P304

Q37139413-E0BD6FE2-A42F-4A05-8FA8-3A8BD4856729

P31

Q37139413-51BC1B71-8545-40C8-8CF9-02CF9669EA29

P356

Q37139413-CDB941DE-0AC9-489A-ADD4-B1C090416014

P433

Q37139413-6475A12B-A4D4-4454-A552-FF70547191D6

P478

Q37139413-19F95293-C3E8-4691-BA32-44C4331BE582

P577

Q37139413-9EC2E528-A468-4D52-8312-492062D95271

P5875

Q37139413-6A3CAC89-2269-40CE-BA33-F8C00FE6C2BD

P698

Q37139413-D74F6DB4-EBE3-4AB8-8B23-E54BB1230B9F

P921

Q37139413-BC97086D-52A8-4D4D-BA39-9D33266B4FA8

P932

Q37139413-7F0FE7E0-0F3F-42A1-964F-233E373E7D67

P356

S10555-008-9143-X

P1433

Cancer and Metastasis Reviews

P1476

Clinical biomarkers of angiogenesis inhibition.

@en

P2093

Aaron P Brown

http://www.w3.org/2001/XMLSchema#string

Deborah E Citrin

http://www.w3.org/2001/XMLSchema#string

Kevin A Camphausen

http://www.w3.org/2001/XMLSchema#string

P2860

Genes expressed in human tumor endothelium

Proteomics of human umbilical vein endothelial cells applied to etoposide-induced apoptosis

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

Probing physiology and molecular function using optical imaging: applications to breast cancer

Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Tumor angiogenesis: therapeutic implications

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

P2888

s10555-008-9143-x

P304

415-434

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10555-008-9143-X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5437671

http://www.w3.org/2001/XMLSchema#string

P698

18414993

http://www.w3.org/2001/XMLSchema#string

P921

P932

2676436

http://www.w3.org/2001/XMLSchema#string